TH vs. AEZS, HBP, BCT, MBX, SVA, ONC, APS, MDNA, MDP, and CWEB
Should you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include Aeterna Zentaris (AEZS), Helix BioPharma (HBP), BriaCell Therapeutics (BCT), Microbix Biosystems (MBX), Sernova (SVA), Oncolytics Biotech (ONC), Aptose Biosciences (APS), Medicenna Therapeutics (MDNA), Medexus Pharmaceuticals (MDP), and Charlotte's Web (CWEB). These companies are all part of the "medical" sector.
Aeterna Zentaris (TSE:AEZS) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, community ranking, profitability and dividends.
Aeterna Zentaris has higher earnings, but lower revenue than Theratechnologies. Aeterna Zentaris is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.
In the previous week, Theratechnologies' average media sentiment score of 0.00 equaled Aeterna Zentaris'average media sentiment score.
Aeterna Zentaris has a net margin of 0.00% compared to Aeterna Zentaris' net margin of -23.04%. Theratechnologies' return on equity of -61.34% beat Aeterna Zentaris' return on equity.
Theratechnologies received 261 more outperform votes than Aeterna Zentaris when rated by MarketBeat users. However, 88.89% of users gave Aeterna Zentaris an outperform vote while only 63.44% of users gave Theratechnologies an outperform vote.
Aeterna Zentaris has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, Theratechnologies has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.
Theratechnologies has a consensus target price of C$5.50, suggesting a potential upside of 231.33%. Given Aeterna Zentaris' higher possible upside, analysts clearly believe Theratechnologies is more favorable than Aeterna Zentaris.
0.8% of Aeterna Zentaris shares are owned by institutional investors. Comparatively, 50.7% of Theratechnologies shares are owned by institutional investors. 4.0% of Aeterna Zentaris shares are owned by insiders. Comparatively, 6.3% of Theratechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Theratechnologies beats Aeterna Zentaris on 9 of the 15 factors compared between the two stocks.
Get Theratechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for TH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Theratechnologies Competitors List
Related Companies and Tools
